Wilms Tumor Suppressor, WT1, Cooperates with MicroRNA-26a and MicroRNA-101 to Suppress Translation of the Polycomb Protein, EZH2, in Mesenchymal Stem Cells*

Hereditary forms of Wilms arise from developmentally arrested clones of renal progenitor cells with biallelic mutations of WT1; recently, it has been found that Wilms tumors may also be associated with biallelic mutations in DICER1 or DROSHA, crucial for miRNA biogenesis. We have previously shown that a critical role for WT1 during normal nephrogenesis is to suppress transcription of the Polycomb group protein, EZH2, thereby de-repressing genes in the differentiation cascade. Here we show that WT1 also suppresses translation of EZH2. All major WT1 isoforms induce an array of miRNAs, which target the 3′ UTR of EZH2 and other Polycomb-associated transcripts. We show that the WT1(+KTS) isoform binds to the 5′ UTR of EZH2 and interacts directly with the miRNA-containing RISC to enhance post-transcriptional inhibition. These observations suggest a novel mechanism through which WT1 regulates the transition from resting stem cell to activated progenitor cell during nephrogenesis. Our findings also offer a plausible explanation for the fact that Wilms tumors can arise either from loss of WT1 or loss of miRNA processing enzymes.

[1]  Esther Rheinbay,et al.  Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. , 2010, Cell stem cell.

[2]  R. Gregory,et al.  Many roads to maturity: microRNA biogenesis pathways and their regulation , 2009, Nature Cell Biology.

[3]  M. Swanson,et al.  MicroRNAs in mammalian development and tumorigenesis. , 2006, Birth defects research. Part C, Embryo today : reviews.

[4]  Jacek Krol,et al.  Structural Aspects of MicroRNA Biogenesis , 2004, IUBMB life.

[5]  M. Ladomery,et al.  The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. , 2008, Biochimica et biophysica acta.

[6]  Peter A. Jones,et al.  The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the Polycomb group protein EZH2 in cancer , 2009, Cell cycle.

[7]  W. Foulkes,et al.  Biallelic DICER1 mutations occur in Wilms tumours , 2013, The Journal of pathology.

[8]  Yong Zhao,et al.  A developmental view of microRNA function. , 2007, Trends in biochemical sciences.

[9]  M. Rivera,et al.  Wilms' tumour: connecting tumorigenesis and organ development in the kidney , 2005, Nature Reviews Cancer.

[10]  M. Ladomery,et al.  Multiple roles for the Wilms' tumor suppressor, WT1. , 1999, Cancer research.

[11]  P. Grundy,et al.  Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour , 2014, Nature Communications.

[12]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[13]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[14]  P. Romaniuk,et al.  Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1. , 2001, Biochemistry.

[15]  M. Ladomery,et al.  The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[16]  Peter A. Jones,et al.  The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. , 2009, Cancer research.

[17]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[18]  M. Ladomery,et al.  New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes. , 2008, American journal of physiology. Renal physiology.

[19]  V. Kim,et al.  Biogenesis of small RNAs in animals , 2009, Nature Reviews Molecular Cell Biology.

[20]  V. Huff,et al.  Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one‐third of tumors , 2008, Genes, chromosomes & cancer.

[21]  N D Hastie,et al.  RNA binding by the Wilms tumor suppressor zinc finger proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Gessler,et al.  Target genes of the WNT/β‐catenin pathway in Wilms tumors , 2006 .

[23]  D. Housman,et al.  Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product , 1995, Molecular and cellular biology.

[24]  D. Corey,et al.  Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression. , 2012, Nucleic acid therapeutics.

[25]  D. Housman,et al.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus , 1990, Cell.

[26]  K. Miyagawa,et al.  Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing , 1995, Cell.

[27]  Zissimos Mourelatos,et al.  The microRNA world: small is mighty. , 2003, Trends in biochemical sciences.

[28]  A. Reeve,et al.  Sequential WT1 and CTNNB1 mutations and alterations of β-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies , 2006, Journal of Clinical Pathology.

[29]  M. Niksic,et al.  The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. , 2003, Human molecular genetics.

[30]  Murielle M. Akpa,et al.  Wilms Tumor Suppressor, WT1, Suppresses Epigenetic Silencing of the β-Catenin Gene* , 2014, The Journal of Biological Chemistry.

[31]  Chung F. Wong,et al.  MicroRNA-26a Targets the Histone Methyltransferase Enhancer of Zeste homolog 2 during Myogenesis* , 2008, Journal of Biological Chemistry.

[32]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[33]  D. Housman,et al.  Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. , 1991, American journal of human genetics.

[34]  K. Miyagawa,et al.  Does the Wilms’ tumour suppressor gene, WT1, play roles in both splicing and transcription? , 1995, Journal of Cell Science.